Thrombus Aspiration and Pathology and OCT Study
Launched by FUJITA HEALTH UNIVERSITY ·
Trial Information
Current as of September 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a heart condition called acute coronary syndrome (ACS), which happens when the blood flow to the heart is suddenly blocked, often due to a build-up or damage in the arteries. The study focuses on understanding the types of blockages or “plaque problems” that cause these events by using a special imaging technique called OCT and by examining material removed from the blocked artery during treatment. Doctors want to learn more about how well OCT can identify different kinds of artery damage, which could help improve how patients are diagnosed and treated in the future.
The trial is open to adults of all genders who are experiencing ACS with a large amount of blood clot in their arteries and who are going to receive a procedure called percutaneous coronary intervention (PCI) to restore blood flow. Participants will undergo a standard treatment where doctors remove some of the clot material before opening the artery, and this material will be studied closely to understand the cause of the blockage. Joining this study means you will receive care as usual, with the added benefit that your treatment will help doctors learn more about heart artery problems and improve care for future patients.
Gender
ALL
Eligibility criteria
About Fujita Health University
Fujita Health University is a premier institution dedicated to advancing medical research and education, with a strong emphasis on clinical trials that enhance healthcare outcomes. Located in Japan, the university combines cutting-edge scientific inquiry with a commitment to patient-centered care, fostering collaboration among researchers, clinicians, and healthcare professionals. With a focus on innovative therapies and evidence-based practices, Fujita Health University aims to contribute significantly to the field of medicine through rigorous clinical trials that address pressing health challenges and improve the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
YUKIO OZAKI, MD, PhD
Principal Investigator
Fujita Health University, Aichi, Japan
Eloisa Arbustini, MD
Study Chair
IRCCS Foundation Policlinico San Matteo, Pavia, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported